Enso Vascular is developing a purpose-built topical patch that prepares the vascular access site before the needle — reducing complications, streamlining procedures, and improving outcomes for millions of patients worldwide.
Interventional medicine has shifted decisively toward radial-first approaches, yet clinicians still lack a dedicated tool to prepare the access site. The result is preventable complications, procedural delays, and patient discomfort.
Radial artery spasm occurs in up to 25% of transradial procedures — causing patient pain, procedural failure, and crossover to alternative access sites.
Current approaches to site preparation are ad hoc, inconsistent, and add unpredictable time to setup. No standardized protocol exists.
Despite billions of procedures annually, there is no FDA-approved product designed specifically to optimize the access site before needle insertion.
The Enso Vascular Patch delivers a targeted combination of therapeutic agents directly to the access site — providing both local tissue conditioning and vessel preparation in a single, easy-to-use application. One dual-action step, addressing the two primary barriers to successful access.
Targeted delivery of anesthetic agents to the access site for rapid, localized effect — without the pain of a needle.
A proprietary formulation promotes favorable vessel conditions prior to catheter insertion, addressing reactivity at the source.
Unlike systemic approaches or general-purpose topical anesthetics, our platform is built for the unique pharmacological and anatomical requirements of vascular access — reaching therapeutic concentrations at the depth that matters, within a clinically practical window.
Optimized for intradermal and subdermal drug deposition in the tissue layers overlying the target vessel — not diffuse systemic transdermal absorption.
Two complementary mechanisms in a single formulation, addressing both pain and vessel reactivity at the access site simultaneously.
A simple apply-and-wait protocol that drops into existing procedural workflows — no new training and no additional equipment.
Causes pain itself, distorts tissue anatomy, and can induce the very vasospasm it aims to prevent. Anesthesia only — no vessel conditioning.
Products like EMLA require 60+ minutes for adequate depth and offer no anti-spasm properties. Not designed for the access workflow.
Administered after puncture — they cannot prevent spasm on the initial attempt, and require mixing and injection that add complexity and cost.
Dual-action anesthesia and vessel conditioning through non-invasive topical delivery — applied pre-procedurally, inside the clinical workflow window.
Provisional patent protection has been filed covering the novel combination formulation, delivery methodology, and specific application at vascular access sites — designed for durable protection across the key dimensions of our competitive advantage.
Developed through an FDA pathway appropriate for combination topical drug products. By leveraging well-characterized active ingredients with established safety profiles, we aim to streamline development and reduce clinical risk relative to novel molecular entities.
Our lead program is advancing through formulation development toward the SATORI pilot study, on a regulatory path built from well-characterized active ingredients.
Established Enso Vascular, Inc. Initiated formulation development with a contract manufacturing partner and began iterative optimization of the drug-delivery profile.
In-vitro permeation testing (IVPT) demonstrating therapeutic drug concentrations at target tissue depth. Provisional patent filing covering formulation and method of use.
IRB application for the SATORI pilot trial at an academic medical center. Final formulation optimization and clinical supply manufacturing.
First-in-human evaluation of the Enso Vascular Patch in patients undergoing transradial cardiac catheterization. Primary endpoints: safety, tolerability, and preliminary efficacy signals.
Pre-IND interactions with FDA. Pivotal trial design informed by pilot data, with evaluation of expansion indications including IV access and dialysis.
There is no FDA-approved product designed to optimize the vascular access site before needle insertion. We intend to define and lead this category.
Global vascular access device and preparation market across all access types and clinical settings.
Interventional radial and high-value vascular access procedures in the US and EU where site optimization has the greatest impact.
Achievable at roughly 5% penetration of the interventional cardiology radial access segment alone.
Existing products address only part of the problem, and none were designed for the vascular access use case.
| Approach | Local anesthesia | Vasodilation | Non-invasive | Pre-procedural | Purpose-built |
|---|---|---|---|---|---|
| Subcutaneous lidocaine | ✓ | ✗ | ✗ | ✓ | ✗ |
| EMLA cream | ~ | ✗ | ✓ | 60+ min | ✗ |
| Intra-arterial cocktails | ✗ | ✓ | ✗ | ✗ | ✗ |
| Nitroglycerin patch | ✗ | ~ | ✓ | ✓ | ✗ |
| Enso Vascular Patch | ✓ | ✓ | ✓ | ✓ | ✓ |
Medical device companies that defined new procedural categories in interventional cardiology have generated significant value. Vascular access site preparation is a similar greenfield: large procedure volumes, clear unmet need, and no incumbent to displace.
First-mover in a new category with provisional IP protection and a clear development path.
Well-characterized ingredients reduce regulatory risk and accelerate time to market.
Massive procedure volume supports rapid revenue scaling at even modest penetration.
Platform potential across multiple vascular access indications multiplies the opportunity.
We welcome inquiries from investors, strategic partners, and clinical collaborators interested in the future of vascular access.
ensovascular@gmail.com →Seed and early-stage investors with interest in medtech, digital health, or specialty pharma.
Medical device and pharmaceutical companies exploring vascular access or topical drug-delivery platforms.
Interventional cardiologists and vascular access specialists interested in trial participation or advisory roles.